
BT Manufacturing
Leader in pure Hypochlorous Acid solutions, offering unmatched efficacy and stability for pathogen control and healing enhancement.
Date | Investors | Amount | Round |
---|---|---|---|
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
* | N/A | $2.0m | Seed |
Total Funding | 000k |
Related Content
Founded in 2013, Briotech is a pioneering manufacturer of pure Hypochlorous Acid (HOCl) formulations, headquartered in Woodinville, WA. The company has established itself as a global leader in HOCl solutions, known for their unmatched efficacy and stability. Briotech's core product, pure HOCl, is a naturally occurring compound produced by white blood cells to combat pathogens such as viruses, bacteria, and fungi. It also plays a crucial role in reducing inflammation, controlling injury responses, and enhancing the healing process.
Briotech serves a diverse range of clients, including healthcare providers, research institutions, and industries requiring effective pathogen control. The company operates in the healthcare and sanitation markets, leveraging its proprietary formulations to offer scalable and affordable solutions with long shelf lives. Briotech's business model revolves around the production and sale of its HOCl formulations, generating revenue through direct sales and partnerships with various industries.
The company's numerous scientific breakthroughs have been documented in studies conducted at prestigious institutes and universities, further solidifying its reputation in the market. Briotech's commitment to innovation and quality has earned it EPA List N approval, ensuring its products meet stringent regulatory standards.
Keywords: Hypochlorous Acid, pathogen control, healthcare, sanitation, inflammation reduction, healing enhancement, proprietary formulations, scientific breakthroughs, EPA approved, scalable solutions.